Rhythm Pharmaceuticals Up 12%; Thursday Is PDUFA Goal Date
June 16 2022 - 3:01PM
Dow Jones News
By Josh Beckerman
Shares of Rhythm Pharmaceuticals Inc., which focuses on drugs
for rare genetic diseases of obesity, were recently up 12%, to
$3.85.
Thursday is the Prescription Drug User Fee Act goal date for the
company's supplemental New Drug Application for Imcivree, for
patients with Bardet-Biedl Syndrome or Alström syndrome. The U.S.
Food and Drug Administration approved the drug in November 2020 for
chronic weight management for patients with three rare genetic
conditions.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 16, 2022 14:46 ET (18:46 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Oct 2023 to Oct 2024
